LncRNA HOXA‑AS2 is a prognostic and clinicopathological predictor in patients with cancer: A meta‑analysis

Xiao,Tijun; Yan,An; Tan,Lifang; Zhu,Hongwei; Gao,Wenzhe

doi:10.3892/ol.2024.14359

LncRNA HOXA‑AS2 is a prognostic and clinicopathological predictor in patients with cancer: A meta‑analysis

Authors:
- Tijun Xiao
- An Yan
- Lifang Tan
- Hongwei Zhu
- Wenzhe Gao
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Shaoyang University, Shaoyang, Hunan 422000, P.R. China, Department of Hepatopancreatobiliary Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China
Published online on: March 22, 2024 https://doi.org/10.3892/ol.2024.14359
Article Number: 226
Copyright: © Xiao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Elevated expression of long non‑coding RNA homeobox A cluster antisense RNA 2 (lncRNA HOXA‑AS2) is known to have prognostic value in various solid tumors. The present meta‑analysis aimed to comprehensively quantify its prognostic significance across a wider spectrum of malignancies and to provide an updated synthesis of evidence that could refine prognostic models. To achieve this aim, multiple databases were carefully searched for lncRNA HOXA‑AS2‑related articles published in the past 10 years. Hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to demonstrate the prognostic value of lncRNA HOXA‑AS2 using Stata 15.0 software. The function of lncRNA HOXA‑AS2 was inferred from its associations with key clinical outcomes such as lymph node metastasis, distant metastasis, tumor stage and tumor size, which may reflect its role in tumor biology. In the present systematic review and meta‑analysis of 454 patients across 7 studies, it was found that high lncRNA HOXA‑AS2 expression was significantly associated with a shorter overall survival (OS) time in patients with cancer (HR=2.14; 95% CI, 1.40‑3.27; P<0.001). High lncRNA HOXA‑AS2 expression was also associated with lymph node metastasis [odds ratio (OR)=2.06; 95% CI, 1.07‑3.99; P=0.032], distant metastasis (OR=2.11; 95% CI, 1.15‑3.88; P=0.016), advanced tumor stage (OR=2.71; 95% CI, 1.50‑4.89; P=0.001) and larger tumor size (OR=2.02; 95% CI, 0.86‑4.78; P=0.006). However, no significant association was observed with age (OR=1.00; 95% CI, 0.63‑1.59; P=0.991) or sex (OR=1.55; 95% CI, 0.72‑3.34; P=0.258). In conclusion, elevated expression of lncRNA HOXA‑AS2 was significantly related to poor clinical outcomes in various cancer types, such as osteosarcoma, non‑small cell lung cancer and papillary thyroid carcinoma, a finding that was further confirmed by the present study. Specifically, the potential of lncRNAHOXA‑AS2 as a biomarker in assessing tumor stage, metastasis risk and OS in patients was demonstrated. However, the results of the present study also indicated that the expression of lncRNA HOXA‑AS2 was not significantly associated with age or sex, suggesting its role in cancer progression might be independent of these factors. This insight may direct future research to place more focus on the relationship between lncRNA HOXA‑AS2 and specific cancer types and clinical characteristics.

View Figures

View References

1	Mattick JS and Makunin IV: Non-coding RNA. Hum Mol Genet. 15:Spec No 1:R17–29. 2006. View Article : Google Scholar : PubMed/NCBI
2	Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG, et al: The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression. Genome Res. 22:1775–1789. 2012. View Article : Google Scholar : PubMed/NCBI
3	Kung JT, Colognori D and Lee JT: Long noncoding RNAs: Past, present, and future. Genetics. 193:651–669. 2013. View Article : Google Scholar : PubMed/NCBI
4	Fatica A and Bozzoni I: Long non-coding RNAs: New players in cell differentiation and development. Nat Rev Genet. 15:7–21. 2014. View Article : Google Scholar : PubMed/NCBI
5	Bhan A, Soleimani M and Mandal SS: Long noncoding RNA and cancer: A new paradigm. Cancer Res. 77:3965–3981. 2017. View Article : Google Scholar : PubMed/NCBI
6	Wang KC and Chang HY: Molecular mechanisms of long noncoding RNAs. Mol Cell. 43:904–914. 2011. View Article : Google Scholar : PubMed/NCBI
7	Schmitt AM and Chang HY: Long noncoding RNAs in cancer pathways. Cancer Cell. 29:452–463. 2016. View Article : Google Scholar : PubMed/NCBI
8	Choudhari R, Sedano MJ, Harrison AL, Subramani R, Lin KY, Ramos EI, Lakshmanaswamy R and Gadad SS: Long noncoding RNAs in cancer: From discovery to therapeutic targets. Adv Clin Chem. 95:105–147. 2020. View Article : Google Scholar : PubMed/NCBI
9	Zhao H, Zhang X, Frazão JB, Condino-Neto A and Newburger PE: HOX antisense lincRNA HOXA-AS2 is an apoptosis repressor in all trans retinoic acid treated NB4 promyelocytic leukemia cells. J Cell Biochem. 114:2375–2383. 2013. View Article : Google Scholar : PubMed/NCBI
10	Feng Y, Hu S, Li L, Peng X and Chen F: Long noncoding RNA HOXA-AS2 functions as an oncogene by binding to EZH2 and suppressing LATS2 in acute myeloid leukemia (AML). Cell Death Dis. 11:10252020. View Article : Google Scholar : PubMed/NCBI
11	Zhang P, Liu L, Zhang W, Fang J, Li G, Zhang L, Li J, Deng X, Ma J, Li K and Chen Z: Effects of long noncoding RNA HOXA-AS2 on the proliferation and migration of gallbladder cancer cells. J Oncol. 2022:60515122022. View Article : Google Scholar : PubMed/NCBI
12	Zhong C, Tao B, Li X, Xiang W, Peng L, Peng T, Chen L, Xia X, You J and Yang X: HOXA-AS2 contributes to regulatory T cell proliferation and immune tolerance in glioma through the miR-302a/KDM2A/JAG1 axis. Cell Death Dis. 13:1602022. View Article : Google Scholar : PubMed/NCBI
13	Wu Q, Lu S, Zhang L and Zhao L: LncRNA HOXA-AS2 activates the notch pathway to promote cervical cancer cell proliferation and migration. Reprod Sci. 28:3000–3009. 2021. View Article : Google Scholar : PubMed/NCBI
14	Jiang L, Wu Z, Meng X, Chu X, Huang H and Xu C: LncRNA HOXA-AS2 facilitates tumorigenesis and progression of papillary thyroid cancer by modulating the miR-15a-5p/HOXA3 axis. Hum Gene Ther. 30:618–631. 2019. View Article : Google Scholar : PubMed/NCBI
15	Zhao Z, Xing Y, Yang F, Zhao Z, Shen Y, Song J and Jing S: LncRNA HOXA-AS2 promotes oral squamous cell proliferation, migration, and invasion via upregulating EZH2 as an oncogene. Technol Cancer Res Treat. 20:153303382110391092021. View Article : Google Scholar : PubMed/NCBI
16	Wang J, Su Z, Lu S, Fu W, Liu Z, Jiang X and Tai S: LncRNA HOXA-AS2 and its molecular mechanisms in human cancer. Clin Chim Acta. 485:229–233. 2018. View Article : Google Scholar : PubMed/NCBI
17	Tierney JF, Stewart LA, Ghersi D, Burdett S and Sydes MR: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
18	Liu Z, Cai L, Liu Y, Chen W and Wang Q: Association between prenatal cadmium exposure and cognitive development of offspring: A systematic review. Environ Pollut. 254:1130812019. View Article : Google Scholar : PubMed/NCBI
19	Zhang L, Yu CH, Guo KP, Huang CZ and Mo LY: Prognostic role of red blood cell distribution width in patients with sepsis: A systematic review and meta-analysis. BMC Immunol. 21:402020. View Article : Google Scholar : PubMed/NCBI
20	Zhang F, Zhang G, Zhang H, Pu X, Chi F, Zhang D, Xin X, Gao M, Luo W and Li X: HOXA-AS2 may be a potential prognostic biomarker in human cancers: A meta-analysis and bioinformatics analysis. Front Genet. 13:9442782022. View Article : Google Scholar : PubMed/NCBI
21	Lu Q, Gao J, Tang S, Li Z, Wang X, Deng C, Hu J, Tao Y and Wang Q: Integrated RNA sequencing and single-cell mass cytometry reveal a novel role of LncRNA HOXA-AS2 in tumorigenesis and sternness of hepatocellular carcinoma. Onco Targets Ther. 13:10901–10916. 2020. View Article : Google Scholar : PubMed/NCBI
22	Qu Y, Wang Y, Wang P, Lin N, Yan X and Li Y: Overexpression of long noncoding RNA HOXA-AS2 predicts an adverse prognosis and promotes tumorigenesis via SOX4/PI3K/AKT pathway in acute myeloid leukemia. Cell Biol Int. 44:1745–1759. 2020. View Article : Google Scholar : PubMed/NCBI
23	Chen R and He P: Long noncoding RNA HOXA-AS2 accelerates cervical cancer by the miR-509-3p/BTN3A1 axis. J Pharm Pharmacol. 73:1387–1396. 2021. View Article : Google Scholar : PubMed/NCBI
24	Cui TJ, Lin GS, Dai YM, Zheng JP, Chen Z, Chen Q, Zheng Y and Lin X: LncRNA HOXA-AS2 regulates microRNA-216a-5p to promote malignant progression of non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 23 (Suppl 3):S264–S273. 2019.PubMed/NCBI
25	Wang L, Wang L and Zhang X: Knockdown of lncRNA HOXA-AS2 inhibits viability, migration and invasion of osteosarcoma cells by miR-124-3p/E2F3. Onco Targets Ther. 12:10851–10861. 2019. View Article : Google Scholar : PubMed/NCBI
26	Xiao S and Song B: LncRNA HOXA-AS2 promotes the progression of prostate cancer via targeting miR-509-3p/PBX3 axis. Biosci Rep. 40:BSR201932872020. View Article : Google Scholar : PubMed/NCBI
27	Yang Z, Zhang F, Cai K and Xu J: Long noncoding RNA HOXA-AS2 facilitates prostate cancer progression by inhibiting miR-885-5p to upregulate KDM5B. Kidney Blood Press Res. 48:45–55. 2023. View Article : Google Scholar : PubMed/NCBI
28	Wu J, Li M and Zhang Y: Long noncoding RNA HOXA-AS2 regulates the expression of SCN3A by sponging miR-106a in breast cancer. J Cell Biochem. 120:14465–14475. 2019. View Article : Google Scholar : PubMed/NCBI
29	Lian Y, Li Z, Fan Y, Huang Q, Chen J, Liu W, Xiao C and Xu H: The lncRNA-HOXA-AS2/EZH2/LSD1 oncogene complex promotes cell proliferation in pancreatic cancer. Am J Transl Res. 9:5496–5506. 2017.PubMed/NCBI
30	Gao Y, Yu H, Liu Y, Liu X, Zheng J, Ma J, Gong W, Chen J, Zhao L, Tian Y and Xue Y: Long non-coding RNA HOXA-AS2 regulates malignant glioma behaviors and vasculogenic mimicry formation via the MiR-373/EGFR axis. Cell Physiol Biochem. 45:131–147. 2018. View Article : Google Scholar : PubMed/NCBI
31	Duan WW, Yang LT, Liu J, Dai ZY, Wang ZY, Zhang H, Zhang X, Liang XS, Luo P, Zhang J, et al: A TGF-β signaling-related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response. CNS Neurosci Ther. Oct 18–2023.(Epub ahead of print). View Article : Google Scholar
32	Zhang Y, Zhuang T, Xin Z, Sun C, Li D, Ma N and Wang X and Wang X: Construction of a necroptosis-related lncRNA signature for predicting prognosis and immune response in kidney renal clear cell carcinoma. Cells. 12:662023. View Article : Google Scholar
33	Doghish AS, Elshaer SS, Fathi D, Rizk NI, Elrebehy MA, Al-Noshokaty TM, Elballal MS, Abdelmaksoud NM, Abdel-Reheim MA, Abdel Mageed SS, et al: Unraveling the role of miRNAs in the diagnosis, progression, and drug resistance of oral cancer. Pathol Res Pract. 253:1550272024. View Article : Google Scholar : PubMed/NCBI
34	Dong X, Fang Z, Yu M, Zhang L, Xiao R, Li X, Pan G and Liu J: Knockdown of long noncoding RNA HOXA-AS2 suppresses chemoresistance of acute myeloid leukemia via the miR-520c-3p/S100A4 axis. Cell Physiol Biochem. 51:886–896. 2018. View Article : Google Scholar : PubMed/NCBI
35	Wang F, Wu D, Chen J, Chen S, He F, Fu H, Wu Q, Liu S, Li X and Wang W: Long non-coding RNA HOXA-AS2 promotes the migration, invasion and stemness of bladder cancer via regulating miR-125b/Smad2 axis. Exp Cell Res. 375:1–10. 2019. View Article : Google Scholar : PubMed/NCBI
36	Chen PY, Li XD, Ma WN, Li H, Li MM, Yang XY and Li SY: Comprehensive transcriptomic analysis and experimental validation identify lncRNA HOXA-AS2/miR-184/COL6A2 as the critical ceRNA regulation involved in low-grade glioma recurrence. Onco Targets Ther. 13:4999–5016. 2020. View Article : Google Scholar : PubMed/NCBI
37	Zhang P, Cao P, Zhu X, Pan M, Zhong K, He R, Li Y, Jiao X and Gao Y: Upregulation of long non-coding RNA HOXA-AS2 promotes proliferation and induces epithelial-mesenchymal transition in gallbladder carcinoma. Oncotarget. 8:33137–33143. 2017. View Article : Google Scholar : PubMed/NCBI
38	Ding J, Xie M, Lian Y, Zhu Y, Peng P, Wang J, Wang L and Wang K: Long noncoding RNA HOXA-AS2 represses P21 and KLF2 expression transcription by binding with EZH2, LSD1 in colorectal cancer. Oncogenesis. 6:e2882017. View Article : Google Scholar : PubMed/NCBI
39	Zhao Q, Zhao S, Li J, Zhang H, Qian C, Wang H, Liu J and Zhao Y: TCF7L2 activated HOXA-AS2 decreased the glucocorticoid sensitivity in acute lymphoblastic leukemia through regulating HOXA3/EGFR/Ras/Raf/MEK/ERK pathway. Biomed Pharmacother. 109:1640–1649. 2019. View Article : Google Scholar : PubMed/NCBI
40	EL Andaloussi S, Mäger I, Breakefield XO and Wood MJ: Extracellular vesicles: Biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 12:347–357. 2013. View Article : Google Scholar : PubMed/NCBI
41	Zhou G and Chen X: Emerging role of extracellular microRNAs and lncRNAs. ExRNA. 1:102019. View Article : Google Scholar
42	Wang Q, Zhang W, Deng C, Lin S and Zhou Y: HOXA-AS2 may predict the prognosis of solid tumors among Chinese patients: A meta-analysis and bioinformatic analysis. Front Oncol. 12:10308252022. View Article : Google Scholar : PubMed/NCBI
43	Lu B, Liu Z, Ji X and Zhang X: Assessment of the prognostic and clinicopathological significance of HOXA-AS2 in human cancers: A systematic review and meta-analysis. Transl Cancer Res. 12:605–615. 2023. View Article : Google Scholar : PubMed/NCBI